SCHEMBL2391793

SCHEMBL2391793

COc1c(Cl)cc(C=O)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.46
KMT2A Q03164 4/20 0.46
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
CYP1A2 P05177 2/20 0.44
TSHR P16473 1/20 0.42
CYP2A6 P11509 1/20 0.41
TPMT P51580 1/20 0.40
CYP3A4 P08684 1/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 4/20 0.38
TDP1 Q9NUW8 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 1/20 0.38
ALPG P10696 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524215 0.88 KMT2A (0.55) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL16411026 0.86 KMT2A (0.41) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL2808932 0.86 TPMT (0.54) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL31063093 0.86 ALDH1A1 (0.47) ALDH1A1KMT2AL3MBTL1CYP1A2TSHR
SCHEMBL25550708 0.85 CYP1A2 (0.48) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL5368739 0.83 KMT2A (0.39) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL24481287 0.82 KMT2A (0.39) ALDH1A1KMT2AGAAKDM4EL3MBTL1
SCHEMBL19358667 0.80 VCAM1 (0.54) ALDH1A1KMT2AKDM4ECYP1A2TSHR
SCHEMBL4006794 0.79 ALDH1A1 (0.55) ALDH1A1CYP1A2CYP2A6CYP3A4CYP2C19
SCHEMBL20607035 0.78 ALDH1A1 (0.46) ALDH1A1KMT2AL3MBTL1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments ALLERGAN, INC. 2003-07-03 US claimed
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2026-04-23 US disclosed
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2025-10-23 US disclosed
US-12234231-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2025-02-25 US disclosed
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103368-A EIF4E inhibitors and uses thereof 皮克医疗公司 2024-05-28 CN disclosed
WO-2024102245-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2024-05-16 WO disclosed
CN-114539249-B Podophyllotoxin derivative tubulin inhibitor, and preparation method and medical application thereof 中国药科大学 2024-01-26 CN disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments ALLERGAN, INC. 2003-07-03 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed
EP-1270559-A1 NOVEL IMIDAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY J. URIACH & CIA. S.A. (ES) 2003-01-02 EP disclosed
US-5002960-A Viricides for combating picornaviruses STERLING DRUG, INC. (US) 1991-03-26 US disclosed
EP-0190817-B1 DOPAMINE-BETA-HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1990-09-05 EP disclosed
US-4939267-A Viricides STERLING DRUG INC. (US) 1990-07-03 US disclosed
US-4857540-A 1-SUBSTITUTED-2-MERCAPTO-(OR AMINOMETHYL-)BENZAMIDAZOLE COMPOUNDS SMITHKLINE BECKMAN CORPORATION (US) 1989-08-15 US disclosed
US-4843087-A OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES STERLING DRUG INC. (US) 1989-06-27 US disclosed
US-4728741-A DOPAMINE BETA-HYDROXYLASE INHIBITOR SMITHKLINE BECKMAN CORPORATION (US) 1988-03-01 US disclosed
EP-0190817-A1 Dopamine-beta-hydroxylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885KMT2A 1931/4885GAA 2552/4885
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments TYR, ALDH2, AOX1 ALDH1A1 4/4885KMT2A 2677/4885GAA 259/4885
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885KMT2A 1931/4885GAA 2552/4885
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY CHRM5, CHRM3, CHRNA3 ALDH1A1 2558/4885KMT2A 3712/4885GAA 4713/4885
US-12234231-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885KMT2A 1931/4885GAA 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.